Table 1

Baseline characteristics of the study population

OHCA-cases
(n=35 195)
Non-OHCA controls
(n=3 51 950)
Age (years), median (IQR)72 (62–81)72 (62–81)
Male sex, n (%)23 519 (66.82)235 190 (66.82)
Comorbidity, n (%)
 Heart failure7136 (20.28)17 285 (4.91)
 Ischaemic heart disease*9316 (26.47)41 992 (11.93)
 Cerebrovascular disease4910 (13.95)30 224 (8.59)
 Atrial fibrillation6102 (17.34)26 850 (7.63)
 Peripheral artery disease3914 (11.12)15 798 (4.49)
 Diabetes mellitus5330 (15.14)27 095 (7.70)
 ICD/pacemaker/CRT6978 (19.83)55 877 (15.88)
Concomitant pharmacotherapy, n (%)
 Renin–angiotensin system inhibitors13 105 (37.24)89 481 (25.42)
 Beta blockers8569 (24.35)52 878 (15.02)
 Diuretics17 516 (49.77)107 869 (30.65)
 Calcium channel blockers6978 (19.83)55 877 (15.88)
 Nitrates3962 (11.26)14 416 (4.10)
 Antiarrhythmic drugs class 1 or 3675 (1.92)1887 (0.54)
 Antithrombotics16 075 (45.67)102 020 (28.99)
 QT-prolonging drugs5857 (16.64)28 932 (8.22)
  • Numbers are number (%) unless indicated otherwise.

  • *Including acute myocardial infarction.

  • CRT, cardiac resynchronisation therapy; ICD, implantable cardioverter defibrillator; OHCA, out-of-hospital cardiac arrest.